Retrospective surgical outcomes of Gartland type III supracondylar humeral fractures with absent pulse in children - Takeaways - MDSpire

Retrospective surgical outcomes of Gartland type III supracondylar humeral fractures with absent pulse in children

  • By

  • Maria Rizzo

  • Sabrina Carbone

  • Michela Saracco

  • Fabio Spinetti

  • Emanuela Asunis

  • Gianluca Colella

  • Anna Petrone

  • Gaetano Mignano

  • Fabio Schiano

  • Liberato Carbone

  • Massimo Mariconda

  • June 15, 2026

  • 0 min

Share

  • 1

    Gartland type III supracondylar humeral fractures in children require urgent treatment due to high neurovascular injury risk.

  • 2

    Vascular compromise occurs in 5%-15% of cases, often involving the brachial artery, with presentations ranging from complete ischemia to pink pulseless hand.

  • 3

    In this study, 12 children were analyzed, with 10 presenting ischemia requiring vascular exploration and 2 managed conservatively.

  • 4

    Outcomes showed satisfactory results, but 50% of patients developed angular deformities, and complications included nerve neuropraxia and compartment syndrome.

  • 5

    Management should focus on limb perfusion rather than pulse status, allowing safe observation for patients with preserved perfusion.

Original Source(s)

Retrospective surgical outcomes of Gartland type III supracondylar humeral fractures with absent pulse in children

  • by Maria Rizzo, Sabrina Carbone, Michela Saracco, Fabio Spinetti, Emanuela Asunis, Gianluca Colella, Anna Petrone, Gaetano Mignano, Fabio Schiano, Liberato Carbone, Massimo Mariconda

  • June 15, 2026

Related Content

Case Report: Tibial plateau fracture in Charcot neuroarthropathy: a report of two cases with contrasting outcomes

Rehab May Improve Function in AS

Supervised rehabilitation and exercise-based therapies may improve function, pain, and bone health in ankylosing spondylitis, according to a new review.

FDA Approves Low-Dose Macrocyclic Contrast Agent for MRI

The macrocyclic gadolinium-based contrast agent has a recommended dose of 0.01 mmol/kg actual body weight.